Effect of Non-Surgical Periodontal Treatment on Inflammasome-Related Proteins in Periodontal Diseases
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 45
- 试验地点
- 2
- 主要终点
- Salivary NLRP3 levels (ng/ml)
研究概览
简要总结
The present study aimed to assess the effect of non-surgical periodontal treatment on serum and salivary IL-1beta, IL-18, NLRP3, ASC and Caspase-1 levels in gingivitis and Stage III Grade C periodontitis. 15 periodontally healthy, 15 gingivitis and 15 Stage III Grade C periodontitis patients were enrolled. At baseline, serum and saliva samples were collected and the whole mouth clinical periodontal parameters were recorded. Periodontitis and gingivitis patients received non-surgical periodontal treatment. Clinical parameters were re-measured and samples were re-collected at 1 and 3 months after treatment. Serum and salivary protein levels were analyzed by ELISA. Data were analyzed using appropriate statistical tests.
详细描述
New insights into the first line of immune response to infection and stress signals at the cellular level have reported the participation of cytoplasmic nucleotide-binding domain-like receptors containing multi-protein complexes named inflammasomes. The inflammasomes play a key role in innate immunity by regulating maturation of proinflammatory cytokines of the interleukin 1beta and 18. The inflammasome depends on assembly of a sensor, for instance nod-like receptor family pyrin domaincontaining protein (NLRP), with an adaptor,apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), allowing recruitment and activation of an inflammatory caspase-1. Although different inflammasomes have been described, the NLRP3/ASC/caspase-1 multi-protein complex, known as NLRP3 inflammasome, has been most intensively studied.
Sample size was calculated based on a previous study concerning levels of inflammasome complex proteins in periodontal diseases.To maintain estimates at an optimal level of precision,minimize impact of exclusions and dropouts, and establish significant differences in results at a 95% confidence level, alfa value=0.05, and 83% power.Therefore, the study sample included a total of 45 patients( 15 periodontally healthy, 15 gingivitis, 15 sStage III Grade C Periodontitis). The whole mouth clinical periodontal examination included measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. The presence and type of the alveolar bone loss were assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary. Periodontal status of each patient was evaluated by a single calibrated periodontists with a manual probe. The diagnosis of periodontitis or periodontally health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Periodontally healthy individuals (n=15) in the control group had no sites with PD >3 mm and CAL >2 mm and also no radiographic evidence of alveolar bone loss. BOP was <10% in the whole mouth. Healthy group also exhibited no history of periodontitis. Gingivitis patients had PD≤3 mm, intact periodontium, no destruction in alveolar bone radiographically and BOP>10%. Stage III grade C patient had clinical attachment loss (CAL)≥ 5, radiographic bone loss (RBL) extending to the middle third of root and beyond, ≤ 4 tooth loss due to periodontitis, percentage of bone loss by age is >1.
Treatment The recruited periodontitis and gingivitis patients received conventional quadrant scaling and root planning (SRP). SRP was performed by the same clinician using ultrasonic inserts and manual periodontal curettes. Re-evaluations were performed at 1 and 3 months following the completion of the SRP. No periodontal intervention was carried out in the periodontally healthy controls.
Saliva and Serum Sampling A total of 5 mL of unstimulated whole saliva was collected by passive drool method between 9:00 and 10:00 am. The participants were advised to avoid food consumption for three hours before sample collection. The participants were seated upright and saliva was collected over a period of 5 minutes with instructions to pool saliva in the floor of the mouth and passively drool it into a sterile glass beaker. The saliva samples were centrifuged at 5000 rpm for 10 minutes at room temperature, and supernatants were collected and stored at -80°C. A total of 5 mL of blood was collected from the antecubital fossa by venepuncture method. Serum was isolated from the blood by centrifuging at 3000 rpm for 20 minutes followed by its rapid transfer to a sterile polypropylene tube and storage at -80°C.
Biomarker Immunoassays: Serum and salivary samples of IL-1beta, IL-18, NLRP3, ASC and Caspase-1 were measured by ELISA using commercial kits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •systemically healthy and non-smoker individuals
- •having ≥20 teeth present (except third molars)
- •individuals with periodontally healthy, gingivitis or stage III grade C periodontitis diagnoses
排除标准
- •having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis...
- •usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months.
- •periodontal treatment within the preceding 6 months.
- •pregnant/ lactating/ postmenopausal females.
- •Current orthodontic treatment.
结局指标
主要结局
Salivary NLRP3 levels (ng/ml)
时间窗: from baseline to 1 month and 3 months after treatment
change in salivary NLRP3 levels from baseline to 1 month and 3 months after treatment
Salivary IL-18 levels (pg/ml)
时间窗: from baseline to 1 month and 3 months after treatment
change in salivary IL-18 levels from baseline to 1 month and 3 months after treatment
Salivary Caspase-1 levels (ng/ml)
时间窗: from baseline to 1 month and 3 months after treatment
change in salivary Caspase-1 levels from baseline to 1 month and 3 months after treatment
Salivary IL-1beta levels (pg/ml)
时间窗: from baseline to 1 month and 3 months after treatment
change in salivary IL-1beta levels from baseline to 1 month and 3 months after treatment
Salivary ASC levels (pg/ml)
时间窗: from baseline to 1 month and 3 months after treatment
change in salivary ASC levels from baseline to 1 month and 3 months after treatment
次要结局
- Serum ASC levels (pg/ml)(from baseline to 1 month and 3 months after treatment)
- Serum IL-18 levels (pg/ml)(from baseline to 1 month and 3 months after treatment)
- Serum NLRP3 levels (ng/ml)(from baseline to 1 month and 3 months after treatment)
- Serum Caspase-1 levels (ng/ml)(from baseline to 1 month and 3 months after treatment)
- Serum IL-1beta levels (pg/ml)(from baseline to 1 month and 3 months after treatment)
